Analysts predict EPS of -$0.73 for Marinus Pharmaceuticals Inc. (MRNS)’s current quarter

After finishing at $7.76 in the prior trading day, Marinus Pharmaceuticals Inc. (NASDAQ: MRNS) closed at $7.74, down -0.26%. In other words, the price has decreased by -$0.02 from its previous closing price. On the day, 798487 shares were traded. MRNS stock price reached its highest trading level at $7.92 during the session, while it also had its lowest trading level at $7.62.

Top 5 EV Tech Stocks to Buy for 2023

According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.

Click Here to Download the FREE Report.



Our goal is to gain a better understanding of MRNS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.20 and its Current Ratio is at 10.20. In the meantime, Its Debt-to-Equity ratio is 0.88 whereas as Long-Term Debt/Eq ratio is at 0.88.

Upgrades & Downgrades

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 06 when Austin Charles sold 1,073 shares for $6.49 per share. The transaction valued at 6,964 led to the insider holds 5,277 shares of the business.

Fischer Seth H. Z. sold 1,018 shares of MRNS for $6,658 on Feb 06. The Director now owns 6,026 shares after completing the transaction at $6.54 per share. On Feb 06, another insider, Ezickson Elan, who serves as the Director of the company, sold 750 shares for $6.56 each. As a result, the insider received 4,920 and left with 5,600 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRNS now has a Market Capitalization of 422.65M and an Enterprise Value of 290.02M. For the stock, the TTM Price-to-Sale (P/S) ratio is 18.06 while its Price-to-Book (P/B) ratio in mrq is 4.93. Its current Enterprise Value per Revenue stands at 13.38 whereas that against EBITDA is -15.95.

Stock Price History:

Over the past 52 weeks, MRNS has reached a high of $9.82, while it has fallen to a 52-week low of $3.46. The 50-Day Moving Average of the stock is 7.70, while the 200-Day Moving Average is calculated to be 6.24.

Shares Statistics:

The stock has traded on average 633.96K shares per day over the past 3-months and 861.59k shares per day over the last 10 days, according to various share statistics. A total of 51.77M shares are outstanding, with a floating share count of 47.51M. Insiders hold about 0.10% of the company’s shares, while institutions hold 59.20% stake in the company. Shares short for MRNS as of Apr 27, 2023 were 1.53M with a Short Ratio of 1.53M, compared to 1.78M on Mar 30, 2023. Therefore, it implies a Short% of Shares Outstanding of 3.07% and a Short% of Float of 3.10%.

Earnings Estimates

Its stock is currently analyzed by 11 different market analysts. On average, analysts expect EPS of -$0.73 for the current quarter, with a high estimate of -$0.5 and a low estimate of -$0.8, while EPS last year was -$1.06. The consensus estimate for the next quarter is -$0.74, with high estimates of -$0.53 and low estimates of -$0.79.

Analysts are recommending an EPS of between -$2.25 and -$3.1 for the fiscal current year, implying an average EPS of -$2.86. EPS for the following year is -$2.54, with 11 analysts recommending between -$1.62 and -$3.64.

Revenue Estimates

10 analysts predict $5.3M in revenue for the current quarter. It ranges from a high estimate of $7.06M to a low estimate of $4.4M. As of the current estimate, Marinus Pharmaceuticals Inc.’s year-ago sales were $1.79M, an estimated increase of 196.10% from the year-ago figure. For the next quarter, 11 analysts are estimating revenue of $6.02M, an increase of 157.30% less than the figure of $196.10% in the same quarter last year. There is a high estimate of $8.03M for the next quarter, whereas the lowest estimate is $5M.

A total of 11 analysts have provided revenue estimates for MRNS’s current fiscal year. The highest revenue estimate was $35.53M, while the lowest revenue estimate was $26M, resulting in an average revenue estimate of $28.88M. In the same quarter a year ago, actual revenue was $25.48M, up 13.40% from the average estimate. Based on 11 analysts’ estimates, the company’s revenue will be $48.93M in the next fiscal year. The high estimate is $75.4M and the low estimate is $27.84M. The average revenue growth estimate for next year is up 69.40% from the average revenue estimate for this year.